HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1783, Issue 10, 2008, Pages 2030-2038

  Scognamiglio, Annamaria ^a   Nebbioso, Angela ^a   Manzo, Fabio ^a,c   Valente, Sergio ^b   Mai, Antonello ^b   Altucci, Lucia ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Cancer; Epidrugs; Epigenetic; HDACs; Signal transduction; Sumoylation

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE INHIBITOR; MC1568; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NUCLEAR PROTEIN; PROTEASOME; RAN BINDING PROTEIN 2; RETINOIC ACID RECEPTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DEACETYLATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME REPRESSION; EPIGENETICS; GENE ACTIVATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE; PRIORITY JOURNAL; SUMOYLATION;

APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MOLECULAR CHAPERONES; NUCLEAR PORE COMPLEX PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; SUMO-1 PROTEIN; TRANS-ACTIVATION (GENETICS);

EID: 50849143144     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2008.07.007     Document Type: Article

References (65)

1. Jenuwein T. Re-SET-ting heterochromatin by histone methyltransferases. Trends Cell Biol. 11 (2001) 266-273
2. Kouzarides T. Wellcome Trust Award Lecture. Chromatin-modifying enzymes in transcription and cancer. Biochem. Soc. Trans. 31 (2003) 741-743
3. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 9 (1999) 40-48
4. Das C., and Kundu T.K. Transcriptional regulation by the acetylation of nonhistone proteins in humans - a new target for therapeutics. IUBMB Life 57 (2005) 137-149
5. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
6. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1 (2002) 287-299
7. Johnstone R.W., and Licht J.D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer Cell 4 (2003) 13-18
8. Marks P.A., Richon V.M., Breslow R., and Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13 (2001) 477-483
9. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1 (2001) 194-202
10. Marks P.A., Richon V.M., Miller T., and Kelly W.K. Histone deacetylase inhibitors. Adv. Cancer Res. 91 (2004) 137-168
11. Egger G., Liang G., Aparicio A., and Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429 (2004) 457-463
12. Feinberg A.P., and Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 4 (2004) 143-153
13. Feinberg A.P. The epigenetics of cancer etiology. Semin. Cancer Biol. 14 (2004) 427-432
14. Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr. Opin. Oncol. 17 (2005) 55-60
15. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3 (2003) 253-266
16. Ballestar E., and Esteller M. The epigenetic breakdown of cancer cells: from DNA methylation to histone modifications. Prog. Mol. Subcell Biol. 38 (2005) 169-181
17. Fraga M.F., and Esteller M. Towards the human cancer epigenome: a first draft of histone modifications. Cell Cycle 4 (2005)
18. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 629-656
19. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Faretta M., Fuks F., Lo Coco F., Kouzarides T., Nervi C., Minucci S., and Pelicci P.G. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295 (2002) 1079-1082
20. Di Croce L., Buschbeck M., Gutierrez A., Joval I., Morey L., Villa R., and Minucci S. Altered epigenetic signals in human disease. Cancer Biol. Ther. 3 (2004)
21. Giles R.H., Peters D.J., and Breuning M.H. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 14 (1998) 178-183
22. Di Croce L. Chromatin modifying activity of leukaemia associated fusion proteins. Hum. Mol. Genet. 14 Spec No 1 (2005) R77-84
23. Minucci S., Nervi C., Lo Coco F., and Pelicci P.G. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?. Oncogene 20 (2001) 3110-3115
24. Lin R.J., Egan D.A., and Evans R.M. Molecular genetics of acute promyelocytic leukemia. Trends Genet. 15 (1999) 179-184
25. Grozinger C.M., and Schreiber S.L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 9 (2002) 3-16
26. Wang A.H., Bertos N.R., Vezmar M., Pelletier N., Crosato M., Heng H.H., Th'ng J., Han J., and Yang X.J. HDAC 4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol. Cell Biol. 19 (1999) 7816-7827
27. Guardiola A.R., and Yao T.P. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J. Biol. Chem. 277 (2002) 3350-3356
28. Verdin E., Dequiedt F., and Kasler H.G. Class II histone deacetylases: versatile regulators. Trends Genet. 19 (2003) 286-293
29. Gao L., Cueto M.A., Asselbergs F., and Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277 (2002) 25748-25755
30. Khochbin S., and Kao H.Y. Histone deacetylase complexes: functional entities or molecular reservoirs. FEBS Lett. 494 (2001) 141-144
31. Khochbin S., Verdel A., Lemercier C., and Seigneurin-Berny D. Functional significance of histone deacetylase diversity. Curr. Opin. Genet. Dev. 11 (2001) 162-166
32. Marks P.A., Miller T., and Richon V.M. Histone deacetylases. Curr. Opin. Pharmacol. 3 (2003) 344-351
33. Youn H.D., Grozinger C.M., and Liu J.O. Calcium regulates transcriptional repression of myocyte enhancer factor 2 by histone deacetylase 4. J. Biol. Chem. 275 (2000) 22563-22567
34. Grozinger C.M., and Schreiber S.L. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7835-7840
35. Altucci L., Clarke N., Nebbioso A., Scognamiglio A., and Gronemeyer H. Acute myeloid leukemia: therapeutic impact of epigenetic drugs. Int. J. Biochem. Cell Biol. (2005)
36. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., Alvarez R., Schiavone E.M., Ferrara F., Bresciani F., Weisz A., de Lera A.R., Gronemeyer H., and Altucci L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11 (2005) 77-84
37. Clarke N., Nebbioso A., Altucci L., and Gronemeyer H. TRAIL: at the center of drugable anti-tumor pathways. Cell Cycle 4 (2005) 914-918
38. Altucci L., and Gronemeyer H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 1 (2001) 181-193
39. Altucci L., and Gronemeyer H. Retinoids and TRAIL: two cooperating actors to fight against cancer. Vitam. Horm. 67 (2004) 319-345
40. Altucci L., Wilhelm E., and Gronemeyer H. Leukemia: beneficial actions of retinoids and rexinoids. Int. J. Biochem. Cell Biol. 36 (2004) 178-182
41. Altucci L., Rossin A., Raffelsberger W., Reitmair A., Chomienne C., and Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 7 (2001) 680-686
42. Altucci L., Rossin A., Hirsch O., Nebbioso A., Vitoux D., Wilhelm E., Guidez F., De Simone M., Schiavone E.M., Grimwade D., Zelent A., de The H., and Gronemeyer H. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase a-mediated desubordination of retinoid × receptor. Cancer Res. 65 (2005) 8754-8765
43. Jimenez-Lara A.M., Clarke N., Altucci L., and Gronemeyer H. Retinoic-acid-induced apoptosis in leukemia cells. Trends Mol. Med. 10 (2004) 508-515
44. A. Insinga, S. Monestiroli, S. Ronzoni, V. Gelmetti, F. Marchesi, A. Viale, L. Altucci, C. Nervi, S. Minucci, P.G. Pellicci, Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway, Nat. Med. 2005 Jan;11(1):71-6 (Electronic publication ahead of print 2004 Dec 26).
45. Clarke N., Jimenez-Lara A.M., Voltz E., and Gronemeyer H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. Embo J. 23 (2004) 3051-3060
46. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., and Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21 (1999) 103-107
47. Ferrara F.F., Fazi F., Bianchini A., Padula F., Gelmetti V., Minucci S., Mancini M., Pelicci P.G., Lo Coco F., and Nervi C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61 (2001) 2-7
48. Jones P.A., and Laird P.W. Cancer epigenetics comes of age. Nat. Genet. 21 (1999) 163-167
49. Mai A., Massa S., Pezzi R., Simeoni S., Rotili D., Nebbioso A., Scognamiglio A., Altucci L., Loidl P., and Brosch G. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J. Med. Chem. 48 (2005) 3344-3353
50. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92 (2000) 1210-1216
51. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., and Richon V.M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60 (2000) 5165-5170
52. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
53. Kelly W.K., Richon V.M., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., Klang M., Schwartz L., Richardson S., Rosa E., Drobnjak M., Cordon-Cordo C., Chiao J.H., Rifkind R., Marks P.A., and Scher H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9 (2003) 3578-3588
54. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., MacGregore-Cortelli B., Tong W., Secrist J.P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P.A., Scher H., and Richon V.M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23 (2005) 3923-3931
55. Kelly W.K. Histone deacetylase inhibitors. Clin. Adv. Hematol. Oncol. 2 (2004) 722-723
56. Adnane J., and Robbins P.D. The retinoblastoma susceptibility gene product regulates Myc-mediated transcription. Oncogene 10 (1995) 381-387
57. Denissov S., van Driel M., Voit R., Hekkelman M., Hulsen T., Hernandez N., Grummt I., Wehrens R., and Stunnenberg H. Identification of novel functional TBP-binding sites and general factor repertoires. EMBO J. 26 (2007) 944-954
58. Inoue S., Mai A., Dyer M.J., and Cohen G.M. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 66 (2006) 6785-6792
59. Zimmermann S., Kiefer F., Prudenziati M., Spiller C., Hansen J., Floss T., Wurst W., Minucci S., and Gottlicher M. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res. 67 (2007) 9047-9054
60. Kirsh O., Seeler J.S., Pichler A., Gast A., Muller S., Miska E., Mathieu M., Harel-Bellan A., Kouzarides T., Melchior F., and Dejean A. The SUMO E3 ligase RanBP2 promotes modification of the HDAC 4 deacetylase. EMBO J. 21 (2002) 2682-2691
61. Zhao X., Sternsdorf T., Bolger T.A., Evans R.M., and Yao T.P. Regulation of MEF2 by histone deacetylase 4-and SIRT1 deacetylase-mediated lysine modifications. Mol. Cell Biol. 25 (2005) 8456-8464
62. Lee S.K., Kim J.H., Lee Y.C., Cheong J., and Lee J.W. Silencing mediator of retinoic acid and thyroid hormone receptors, as a novel transcriptional corepressor molecule of activating protein-1, nuclear factor-kappaB, and serum response factor. J. Biol. Chem. 275 (2000) 12470-12474
63. Chen L., Fischle W., Verdin E., and Greene W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293 (2001) 1653-1657
64. Gao Z., Chiao P., Zhang X., Lazar M.A., Seto E., Young H.A., and Ye J. Coactivators and corepressors of NF-kappaB in IkappaB alpha gene promoter. J. Biol. Chem. 280 (2005) 21091-21098
65. Kramer O.H., Zhu P., Ostendorff H.P., Golebiewski M., Tiefenbach J., Peters M.A., Brill B., Groner B., Bach I., Heinzel T., and Gottlicher M. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. Embo J. 22 (2003) 3411-3420